 |
|
|
| |
EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus
Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects
|
| |
| |
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Kajal Larson1, Alaa Ahmad1, Eoin Coakley1, Ty McClure1, Jingwen Chai1, Daniel Dickerson2, and Nathalie Adda1
1Enanta Pharmaceuticals, Inc., Watertown, Massachusetts, USA; 2PRA Health Sciences -Lenexa, Lenexa, Kansas, USA
|
| |
|
|
|
|
|
